Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan (Part 1 & Part 2) to the European Medicines Agency (EMA) to evaluate the efficacy and safety of CT-P13 SC (Zymfentra) in patients with rheumatoid arthritis.
📊 [Key Disclosure Details & Financial Highlights]
- Overview
- Title: Application for Phase 3 Clinical Trial Plan for CT-P13 SC (Zymfentra) in Europe (Part 1 & 2) (Patients with Rheumatoid Arthritis)
- Application Date: August 26, 2024 (Local Time)
- Regulatory Authority: European Medicines Agency (EMA)
- Board Resolution or Fact Confirmation Date: August 26, 2024
- Clinical Trial Details
- Trial Phase: Global Phase 3 Clinical Trial
- Indication: Rheumatoid Arthritis (RA)
- Clinical Trial Registration Number: EU CT number 2024-510945-32
- Objective: To demonstrate the superiority of CT-P13 SC over placebo in terms of efficacy as determined by clinical response according to ACR20 at Week 12
- Number of Subjects: 189 patients
- Trial Duration: Treatment period of 52 weeks
- Study Design: Randomized, placebo-controlled, double-blind, parallel-group
- Future Plans & Important Regulatory Information
- CT-P13 SC previously completed Phase 3 trials for adult ulcerative colitis and Crohn’s disease, earning market authorizations in major markets including the U.S. and Europe. This Phase 3 trial aims to expand its indication to rheumatoid arthritis.
- Under revised EU Clinical Trials Regulations (effective January 31, 2023), application and approval procedures are split into Part 1 (assessment of trial design and methodology) and Part 2 (assessment of trial sites and execution). This disclosure corresponds to the simultaneous submission of both Part 1 and Part 2; final approval for both parts is required to initiate the trial.
- Statistically, the probability of a clinical-stage drug candidate receiving final market authorization is known to be around 10%, and commercialization plans may be modified or abandoned depending on trial outcomes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Approval Status for Part 1 and Part 2 by the European Medicines Agency (EMA)
This disclosure reports the initial application stage for global Phase 3 clinical trial approval in Europe for rheumatoid arthritis. Tracking whether final approvals for both Part 1 and Part 2 are granted by regulatory authorities after review is important for determining the actual initiation of patient dosing and trial execution. Detailed progress can be verified in subsequent regulatory disclosures and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
